Synchron, based in New York, makes the Stentrode, a BCI delivered through the jugular vein to sit in a blood vessel over the motor cortex, avoiding open brain surgery. It raised a $200 million Series D in 2025 to prepare a pivotal trial and commercial launch.
At a glance
| Price from | Not public |
| Best for | Patients with severe paralysis seeking a less invasive implant |
From Synchron's own website.
What stands out
- No open brain surgery needed
- Moving toward a pivotal trial
Worth knowing
- Fewer electrodes than surface or penetrating arrays
- Not yet approved for sale
How it ranks
Synchron is ranked 5th of 10 in Best Medtech Startups (Lister Score 91.8).
#5 in Best Medtech Startups · Lister Score 91.8
Synchron, founded in 2016 and based in Brooklyn, New York, makes the Stentrode, a brain-computer interface delivered through a blood vessel rather than open-brain surgery. It raised a $200 million Series D in November 2025, led by Double Point Ventures, bringing total funding to $345 million.
Synchron says its Series D will fund pivotal trials ahead of a Stentrode launch..
| Rank | Best Medtech Startups | Score |
|---|---|---|
| 1 | Neuralink | 97.0 |
| 2 | Neko Health | 95.7 |
| 3 | Precision Neuroscience | 94.4 |
| 4 | Science Corp | 93.1 |
| 5 | Synchron | 91.8 |
| 6 | Medical Microinstruments (MMI) | 90.5 |
| 7 | ForSight Robotics | 89.2 |
| 8 | Noah Medical | 87.9 |
| 9 | Capstan Medical | 86.6 |
| 10 | Field Medical | 85.3 |
Frequently asked questions
How does Synchron rank on Lister?
Synchron is ranked 5th of 10 in Best Medtech Startups (Lister Score 91.8).
Appears in
- #2 in Best Brain-Computer Interface Companies · Deep Tech
Add this badge to your site
If you work at Synchron, paste this code into your website to show where it ranks on Lister. The badge links to the ranking and updates within a day when the rank changes.